Form 4: Cidara Therapeutics Acquired by Merck for $221.50/Share

Cidara Therapeutics, Inc. completed its merger with a Merck subsidiary, converting all outstanding stock options into cash at $221.50 per common share.

Summary

• Cidara Therapeutics, Inc. was acquired by Merck Sharp & Dohme LLC through its wholly-owned subsidiary, Caymus Purchaser, Inc.
• The merger was completed on January 7, 2026, following a tender offer to acquire all outstanding shares of common stock and Series A Convertible Voting Preferred Stock.
• Each outstanding stock option became fully vested and exercisable immediately prior to the merger's effective time.
• Unexercised options were cancelled and converted into a cash payment equal to the product of the total number of shares subject to the option and the difference between the merger price ($221.50 per Common Share) and the option's exercise price.
• Director Ryan Spencer's stock options, totaling 17,475 shares across three grants, were converted to cash as part of this transaction.

Sentiment

Score: 8

Explanation: The filing reports the successful completion of a merger at a significant premium, resulting in a cash payout for shareholders and option holders. This is a positive outcome for the acquired company's stakeholders, despite the loss of its independent status.

Positives

• Shareholders received $221.50 per Common Share, providing a clear exit and liquidity for their investment.
• Stock option holders, including Director Ryan Spencer, received a cash payout for their vested options, realizing significant value.
• The merger provides a definitive valuation and liquidity event for Cidara's equity holders.

Negatives

• Cidara Therapeutics, Inc. ceases to be an independent publicly traded entity, becoming a wholly-owned subsidiary of Merck.
• Former shareholders no longer participate in the future growth or potential upside of Cidara as a standalone company.

Future Outlook

Cidara Therapeutics, Inc. will operate as a wholly-owned subsidiary of Merck, integrating into Merck's broader pharmaceutical and biotechnology operations. Its independent strategic direction and public reporting will cease.

Industry Context

This acquisition reflects the ongoing consolidation trend in the pharmaceutical and biotechnology sectors, where larger companies like Merck acquire smaller, innovative firms to expand their pipeline, technology, or market share. It indicates Merck's strategic interest in Cidara's assets or capabilities.

Comparison to Industry Standards

• The acquisition price of $221.50 per share would need to be compared to Cidara's pre-announcement stock price and typical acquisition premiums in the biotech sector to assess its fairness.
• Similar acquisitions in the biotech space, such as Pfizer's acquisition of Seagen or AbbVie's acquisition of ImmunoGen, often involve significant premiums over pre-deal trading prices, reflecting the value of pipeline assets and intellectual property.
• The conversion of options to cash at a premium over exercise price is a standard practice in M&A to ensure executive and employee alignment and reward.

Corporate Governance

Stakeholder Impact

• Shareholders: Received $221.50 per common share in cash, providing liquidity and a premium for their investment. They no longer hold shares in an independent Cidara.
• Option Holders (e.g., Ryan Spencer): Received cash payouts for their vested stock options, realizing significant value.
• Employees: Cidara employees are now part of Merck, which could lead to changes in compensation, benefits, and corporate culture, though specific details are not in this filing.
• Customers/Suppliers: Potential changes in relationships or contracts as Cidara integrates into Merck's larger operations.

Next Steps

• Cidara Therapeutics, Inc. will be fully integrated into Merck's operations.
• Cidara's stock will no longer be publicly traded.
• Merck will manage Cidara's assets and pipeline.

Key Dates

Keywords

Cidara Therapeutics, CDTX, Merck, Merck Sharp & Dohme, Caymus Purchaser, merger, acquisition, tender offer, stock options, beneficial ownership, SEC Form 4, Ryan Spencer, pharmaceutical, biotechnology